A study of 351 patients with EGFR mutant lung cancer and brain metastases found that radiation therapy followed by targeted medicines resulted in the longest overall survival, with median survival times of 46 months and 30 months respectively. The findings suggest that a more aggressive approach to treating brain metastases may be the ...
Researchers at Huntsman Cancer Institute identified a protein called Macrophage Stimulating Protein (MSP) that causes bone destruction in metastatic breast cancer. A new drug, Ron inhibitor, blocks the activity of MSP, showing promising results in early clinical trials.
Researchers identify proteins that interact with cancer-related proteins at the center of cellular signaling networks, potentially leading to new chemotherapies. These 'first neighbor' proteins have a significant impact on cancer progression and may be useful drug targets.
Researchers have discovered a common weak point in cancer cell metabolism, allowing them to identify drugs that block backup fuel supply routes. This strategy has shown promise against many hard-to-treat cancers, including sarcomas, and may lead to more effective treatments with fewer side effects.
UTA's integrated cancer research program is strengthening with $6 million grants, bolstering basic research, precision medicine, and screening diagnostics. The University aims to make transformative advances in key areas related to cancer while providing top-notch educational experiences for students.
Researchers found that breast cancer tumors evolve to produce their own estrogen supply, making treatments like aromatase inhibitors ineffective. The study, published in Nature Genetics, aims to increase treatment options for patients whose cancer has returned and spread.
Scientists at the University of North Carolina have discovered a promising new avenue for fighting gastrointestinal cancers by unmasking the previously misunderstood gene Gpr182. The study reveals that Gpr182 could be a key regulator of intestinal stem cell proliferation, and its protein code for a potential drug target.
Researchers at UNC have engineered platelets to carry cancer-fighting antibodies, allowing them to target and kill microtumors before they can grow or spread. This innovative approach has shown promising results in animal studies, potentially offering a new hope for patients with recurring cancer after surgery.
A new technique allows scientists to precisely regulate protein production from genes, enabling the design and study of biological systems. This breakthrough can be used to produce desired products, such as medicines, or study disease-related genes, including those implicated in cancer.
The European Society for Medical Oncology advocates for strict adherence to approval standards and accelerated introduction of biosimilars into clinical settings. This move aims to enhance the sustainability and affordability of cancer treatment, with potential benefits including reduced costs and increased accessibility.
Researchers at Case Western Reserve University have uncovered the structure of a cancer cell receptor protein, paving the way for the development of new cancer-fighting drugs. The study identified key binding sites that can be targeted to modulate the protein's function and prevent tumor growth and metastasis.
The DART trial is a national immunotherapy clinical trial testing leading-edge treatments for rare cancers. Patients will receive ipilimumab and nivolumab combination therapy to fight cancer, with the goal of shrinking tumors and evaluating side effects.
A phase 3 trial found regorafenib significantly improved overall survival in patients with advanced hepatocellular carcinoma (HCC), a form of liver cancer. The study showed that regorafenib can improve survival in patients whose HCC progressed during treatment with sorafenib, an existing drug.
The UK Pancreatic Cancer Research Fund has awarded £9 million in grants to five promising research projects aimed at developing new treatments and diagnostic tools for pancreatic cancer. These projects focus on improving clinical trials, investigating innovative therapies, and understanding the genetic causes of chromosomal instability.
A study by TGen has identified aurintricarboxylic acid (ATA) as a compound that can improve drug development against glioblastoma. ATA blocks the chemical cascade that allows glioblastoma cells to invade normal brain tissue and resist chemotherapy and radiation therapy.
A new drug combination that adds chloroquine to targeted treatment has stabilized a 26-year-old brain cancer patient's disease, increasing both quality and quantity of life. The treatment was effective in two other brain cancer patients with similar diseases.
Researchers at Mayo Clinic found that two common cancer-fighting drugs sparked significant weight loss in morbidly obese mice despite a high-fat diet. The study suggests that these drugs can induce the liver to burn off excess fat, reducing obesity. Further research is needed to explore this potential approach for treating morbid obesity.
Researchers found PDX1 plays a complex role in pancreatic cancer, maintaining cell identity in normal cells but contributing to growth once tumor forms. Blocking PDX1 may actually make the cancer more aggressive by selecting for MYC-expressing cells.
A new study reveals significantly better outcomes for patients with metastatic colorectal cancer when combining vemurafenib with standard treatments. The three-drug combination improved progression-free survival rates and tumor response rates compared to traditional therapies.
The Harrington Discovery Institute has selected three 2016 partnership scholars to support groundbreaking research in Alzheimer's disease and blindness. The scholars will receive funding and expert pharmaceutical guidance to advance their discoveries into new medicines.
The Harrington Discovery Institute has announced grant funding for 11 physician-scientists from premiere universities. The recipients will receive up to $700,000 in capital to support the transition of their work into the private sector.
Research in mice suggests that melanomas and other cancers driven by BRAF V600E mutation will grow faster in response to a high-fat diet. Lipid-lowering agents such as statins can slow tumor growth, even on normal diets. The findings highlight the potential of precision diets tailored to individual patients' cancer mutations.
Lutetium-177-Dotatate has shown improved progression-free survival and response rates compared to octreotide alone in patients with advanced disease. The treatment also experienced higher risk of adverse events, but these were manageable and reversible.
A novel treatment targets Graft-Versus-Host Disease (GVHD) by inhibiting Aurora kinase A and JAK2, preserving immune system function. The study shows promising results in mice, potentially offering a more effective and selective prevention strategy.
The Damon Runyon Cancer Research Foundation has awarded nearly $4 million in fellowships to 16 early-career researchers, providing them with independence to pursue innovative projects. The foundation's Breakthrough Scientist Awards also recognize three researchers who have made paradigm-shifting breakthroughs in cancer research.
A University of North Carolina researcher argues that integrating patient-reported symptoms into clinical practice can improve patient outcomes. Despite demonstrated benefits, cost and technology barriers prevent the widespread adoption of electronic symptom reporting.
Researchers at McGill University Health Centre have made a groundbreaking epigenetic modification that may improve treatment options for 15% of patients with head and neck cancer. The discovery could lead to targeted, more effective treatments with fewer side effects.
A Phase 1 clinical trial found that tucatinib significantly improved outcomes in heavily pretreated patients with HER2+ breast cancer. The drug demonstrated stable disease at 24 weeks or more in 27% of patients, showcasing its potential as a game-changing treatment option.
Researchers found that increasing niacin levels boosts NAD compound for energy generation and DNA repair, potentially protecting against Parkinson's. The study suggests repurposing cancer drugs to protect faulty mitochondria in Parkinson's disease.
Researchers have discovered that Dab2 controls a population of fat stem cells that slowly disappears with maturity. This finding may reinforce the importance of steering children away from high-fat diets and lead to new pharmaceutical strategies to combat childhood obesity.
A study found that adults who performed the recommended amount of weekly physical activity in one or two sessions had lower risks for death from all causes, cardiovascular disease, and cancer. The risk reductions were similar among weekend warriors and insufficiently active adults.
Researchers at Mayo Clinic have identified a key drug target, CDK4/6, which regulates the spread of triple-negative breast cancer. The study found that inhibiting this protein with CDK 4/6 inhibitors can prevent the metastasis of triple-negative breast cancer to distant organs.
A study published in JAMA Internal Medicine found that men and women who engage in physical activity on just one or two occasions per week have a lower risk of death from all causes, cardiovascular disease, and cancer. The 'weekend warriors' spent an average of 300 minutes per week doing moderate- to vigorous-intensity physical activity.
Researchers at the University Health Network have discovered a genetic fingerprint that explains why up to 30% of men with localized prostate cancer develop aggressive disease after radiotherapy or surgery. This finding could help clinicians personalize effective treatments from diagnosis, leading to improved cure rates.
Researchers found that tumors shed between seven and 18 mutations in neoantigen-coding genes after developing resistance to immunotherapy drugs. This phenomenon could lead to new ways to improve current cancer immunotherapies.
A study by Yale researchers found that older lung cancer patients can spend an average of one in three days interacting with the healthcare system within the first 60 days after surgery or radiation therapy. Patients with a higher number of medical conditions treated with surgery had the most post-treatment burdens.
Scientists have identified the key molecule YAP that enables cancer cells to break free from their surroundings and continue growing and spreading. By understanding how YAP is controlled in cancer cells, researchers hope to find new ways to treat or prevent the spread of cancer.
Researchers at Penn State have developed a novel biodegradable nanoparticle-based system that utilizes immune cells to target and deliver cancer-fighting drugs directly to tumors. This innovative approach combines the body's natural immune response with targeted delivery, showing promise for effective treatment of various cancers.
Researchers at Michigan State University have discovered a chemical compound that can stop the spread of melanoma cells by up to 90 percent. The compound targets a gene's ability to produce RNA molecules and proteins in melanoma tumors, effectively shutting down the disease's progression.
A study published in Journal of Clinical Oncology found that new therapies for non-small cell lung cancer resulted in a median 1.5-month survival increase, but this gain was largely offset by higher outpatient spending due to the expensive medications.
Researchers at UNC-Chapel Hill have developed a breakthrough technique that uses light to activate a drug stored in circulating red blood cells. This method could drastically reduce the amount of a drug needed to treat disease and thus side effects.
The study reveals how Piperlongumine converts to an active drug that targets and silences the GSTP1 gene, which is often overactive in tumors. This breakthrough provides new hope for developing cancer therapies using natural compounds.
Legumain (LGMN) is a cysteine protease over-expressed in tumor microenvironment, facilitating tumour growth and metastasis. Targeting LGMN directly or as a prodrug activator may offer promising cancer management strategies.
Research found no association between high monitoring (health detail oriented) and more information receipt for RA patients, while high blunting was linked to more info for OA patients. This challenges typical patterns in acute and chronic disease coping literature.
Molecular imaging techniques have the potential to revolutionize cancer diagnosis, monitoring, and treatment by providing non-invasive alternatives to traditional biopsies. By identifying specific biomarkers, these methods can help doctors choose the most effective treatments, minimize side effects, and predict patient outcomes.
A combination of metformin and syrosingopine drives cancer cells to programmed 'suicide' by blocking their energy supply, inhibiting growth and inducing tumor cell death. The treatment shows promise for targeting the energy needs of tumor cells.
A study published in Nature discovered that fat utilization is required for the development and growth of lymphatic vessels, a key route for cancer cell spread. Researchers found that inhibiting fat usage can control lymphatic vessel growth, offering new avenues for preventing metastasis and treating complications like lymphedema.
A new study reveals that cancer cells can develop resistance to proteasome inhibitors by suppressing the expression of proteasome subunits, leading to a broadly altered cell state with unique vulnerabilities. This finding may expose opportunities for targeted therapies that can be effective against diverse cancers.
A team of researchers used mathematical models to study the emergence of treatment-resistant populations in bacteria and cancer cells. They found that biological redundancy can lead to bet-hedging, a mechanism that allows cells to survive even when faced with catastrophic environmental changes. The study suggests that traditional strat...
Scientists at InSilico Medicine developed a proof-of-concept AI model using Generative Adversarial Autoencoders (AAEs) to generate molecular fingerprints of cancer-killing molecules. The study demonstrates the potential for AI to accelerate pharmaceutical R&D and improve clinical trial success rates.
A major clinical trial has found that adding bortezomib to a standard two-drug regimen significantly prolongs the time before multiple myeloma cancer returns, giving patients about another year of remission. The study also shows that patients who receive this combination therapy live an average of six years after initial treatment.
Researchers discovered an obesity-linked protein FTO's role in leukemia cell growth, survival, and drug response. FTO modulates gene expression by altering RNA modification, leading to cancer-promoting effects.
Scientists found that defects in ARID1A gene caused sensitivity to ATR inhibitors, potentially personalizing treatment for cancer patients. The research could lead to identifying patients who will benefit most from the new drugs.
Researchers developed iCAGES, a computational tool that integrates whole genome-based approach to identify individual cancer driver genes and select treatment options. The tool was found to be superior in predicting cancer drivers and identifying beneficial treatments compared to other computational tools.
Scientists have discovered a potential biomarker, GHRH-R, for gastric cancer, which can aid in earlier diagnoses and better staging. The team also found that the GHRH-R antagonist MIA-602 inhibited gastric cancer growth in cell lines and human xenografts.
UT Southwestern Medical Center researchers developed a nanosensor that amplifies pH signals in tumor cells, distinguishing them from normal cells. The sensor helps surgeons see tumors better during surgery, potentially improving survival and quality of life for cancer patients.
Regular NSAID use associated with a 66% increased risk of dying from endometrial cancer, particularly among those who had used NSAIDs for over 10 years. However, the association did not apply to more aggressive Type 2 cancers.
A study found that cancer patients spend a significant portion of their household income on treatment, transport, and childcare. The economic burden is often referred to as the 'financial toxicity' of cancer.
Researchers have identified a new way of blocking cancer cell invasion using calcium channel blockers, which can stop breast and pancreatic cancer from spreading. The team discovered that these drugs target the sticky finger-like structures on cancer cells, rendering them inactive.
A study by Lawson Research Institute has discovered that the Retinoblastoma protein works with EZH2 to silence repetitive DNA sequences, potentially leading to enhanced therapies for cancer and HIV. The research suggests that targeting these proteins could reveal viral hiding places in immune memory cells, allowing for new treatments.